{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:11:04Z","timestamp":1761430264355,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,5,1]],"date-time":"2001-05-01T00:00:00Z","timestamp":988675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2001,5]]},"DOI":"10.1080\/146532401753174034","type":"journal-article","created":{"date-parts":[[2002,10,28]],"date-time":"2002-10-28T14:38:48Z","timestamp":1035815928000},"page":"203-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM\u2013CAMPATH (\u00b1 fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion"],"prefix":"10.1016","volume":"3","author":[{"given":"R.J.","family":"Lush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.M.","family":"Cull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.I.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pagliuca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.E.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mahendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.F.","family":"Craddock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Liu Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.G.","family":"Prentice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.N.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.H.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1080\/146532401753174034_bib1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1080\/146532401753174034_bib2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V89.3.814","article-title":"Comparison between conventional salvage chemotherapy with autografting for recurrent or refractory Hodgkin's disease","volume":"89","author":"Yuen","year":"1997","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive NHL","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1080\/146532401753174034_bib4","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood.V88.7.2780.bloodjournal8872780","article-title":"High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission","volume":"88","author":"Freedman","year":"1996","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701089","article-title":"Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998","volume":"21","author":"Goldman","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/146532401753174034_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","article-title":"International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury","volume":"1","author":"Shipp","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib7","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","article-title":"Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation","volume":"77","author":"Jones","year":"1991","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib8","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","article-title":"Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease","volume":"14","author":"Gajewski","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib10","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1200\/JCO.1992.10.11.1690","article-title":"Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data","volume":"10","author":"Chopra","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.1995.13.3.596","article-title":"High-dose cyclophosphamide, carmustine and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy","volume":"13","author":"Demirer","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib12","first-page":"1832","article-title":"Allogeneic bone marrow transplantation for low-grade lymphoma","volume":"92","author":"Van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib13","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin's disease. [European Group for Blood and Bone Marrow Transplantation.]","volume":"14","author":"Milpied","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib14","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V84.4.1050.1050","article-title":"Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma","volume":"84","author":"Ratanatharathorn","year":"1994","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib15","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.1182\/blood.V90.10.4201","article-title":"Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma","volume":"90","author":"Verdonck","year":"1997","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic haematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft-versusleukaemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib18","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using a fludarabinebased non-myeloablative chemotherapy and allogeneic blood progenitor transplantation as treatment for lymphoid malignancy","volume":"8","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib19","first-page":"348a","article-title":"Transplant lite using fludarabine-cyclophosphamide (FC) for low-grade lymphoma (LGL)","volume":"94","author":"Khouri","year":"1999","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1080\/146532401753174034_bib20","first-page":"393a","article-title":"Reduced toxicity and transplant-related mortality (TRM) following nonmyeloablative peripheral blood stem cell transplantation for malignant disease","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib21","first-page":"62a","article-title":"Allogeneic stem cell transplantation with fludarabine based less intensive conditioning as adoptive immunotherapy in advanced Hodgkin's disease","volume":"19","author":"Anderlini","year":"2000","journal-title":"Proc Am Assoc Clin Oncol"},{"key":"10.1080\/146532401753174034_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.bmt.1702204","article-title":"Mini-allografts: ongoing trials in humans","volume":"25","author":"Carella","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/146532401753174034_bib23","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1080\/146532401753174034_bib24","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of highdose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease. A single centre 8 year study of 155 patients","volume":"81","author":"Chopra","year":"1993","journal-title":"Blood"},{"key":"10.1080\/146532401753174034_bib25","first-page":"321","article-title":"High-dose melphalan allows durable engraftment of allogeneic bone marrow","volume":"15","author":"Van Beisen","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1080\/146532401753174034_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/oxfordjournals.annonc.a010369","article-title":"Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk lymphoma","volume":"10","author":"Przepiorka","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1080\/146532401753174034_bib27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.01879.x","article-title":"Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM\u2013CAMPATH conditioning: an effective regimen with low procedurerelated toxicity","volume":"108","author":"Cull","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1080\/146532401753174034_bib28","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/eji.1830181006","article-title":"Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies","volume":"18","author":"Bindon","year":"1988","journal-title":"Eur J Immunol"},{"key":"10.1080\/146532401753174034_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0039.1990.tb01767.x","article-title":"The CAMPATH-1 antigen (CD52)","volume":"35","author":"Hale","year":"1990","journal-title":"Tissue Antigens"},{"key":"10.1080\/146532401753174034_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/jcp.47.4.313","article-title":"Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas","volume":"47","author":"Salisbury","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1080\/146532401753174034_bib31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1080\/146532401753174034_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1046\/j.1365-2141.1999.01709.x","article-title":"Comparative serial quantitative measurements of chimaerism following unmanipulated allogeneic transplantation of peripheral blood stem cells and bone marrow","volume":"107","author":"Miflin","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1080\/146532401753174034_bib33","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardise response criteria for non-Hodgkin's lymphomas. [NCI Sponsored International Working Group.]","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1957","journal-title":"J Am Stat Assoc"},{"key":"10.1080\/146532401753174034_bib35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0140-6736(91)90609-S","article-title":"GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen","volume":"338","author":"LaPorte","year":"1991","journal-title":"Lancet"},{"key":"10.1080\/146532401753174034_bib36","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2000.18.23.3918","article-title":"Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma","volume":"18","author":"Carella","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1080\/146532401753174034_bib37","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/sj.bmt.1702392","article-title":"Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma","volume":"25","author":"Nagler","year":"2000","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324901709814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324901709814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T22:07:56Z","timestamp":1761430076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324901709814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["S1465324901709814"],"URL":"https:\/\/doi.org\/10.1080\/146532401753174034","relation":{},"ISSN":["1465-3249"],"issn-type":[{"type":"print","value":"1465-3249"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM\u2013CAMPATH (\u00b1 fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1080\/146532401753174034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}